In the context of the coronavirus pandemic, according to a recent report on the management of patients with renal, germ-cell, urothelial, and prostate cancer, chemotherapy should be delayed, while androgen receptor signaling inhibitors (ARSI) treatment should continue, thus acting as a chemotherapy replacement (7). This evidence concerns the gene AR and prostate carcinoma.